Clinical trial
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
NCT00077441 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00077441 |
|---|---|
| Title | Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) |
| Official title | Phase II Trial of PS-341 in Patients With Hepatocellular Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer |
| Intervention type | Drug, Other |
| Interventions | bortezomib, laboratory biomarker analysis |
| Enrollment | 55 |
| Start date | Apr 1, 2005 |
| Primary completion | Jun 1, 2006 |
| First posted | Feb 12, 2004 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: